NCT00880503 is a clinical trial in Breast Carcinoma, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT00880503?

NCT00880503 is sponsored by National Cancer Institute (NCI).

What condition does NCT00880503 study?

NCT00880503 studies Breast Carcinoma, Breast Cancer, Medullary Thyroid Carcinoma.

Is NCT00880503 still recruiting?

NCT00880503 is currently completed. Last updated 16 December 2019.

Last reviewed 2019-12-16 · How we verify

NCT00880503

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Collection of Tissue Samples for Study of Multidrug Resistance

Completed Last updated 16 December 2019

What this trial tests

trial in Breast Carcinoma in 325 participants. Completed in 8 February 2018.

Timeline

19 December 2003

8 February 2018

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	325
Start date	19 December 2003
Estimated completion	8 February 2018
Sites	1 location across United States

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →
Breast Cancer — all drugs for Breast Cancer →
Medullary Thyroid Carcinoma — all drugs for Medullary Thyroid Carcinoma →

Sponsor

National Cancer Institute (NCI)

Who can join

Adults 18 to 99, any sex, with Breast Carcinoma or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Resistance to cancer chemotherapy develops in patients, rendering certain treatments ineffective. Despite much research, the prevailing cause of drug resistance is not known. One mechanism for drug resistance involves a protein called P-glycoprotein, or Pgp, which reduces the effectiveness of cancer treatments by "pumping" anti-cancer drugs out of tumor cells where they are supposed to work against the disease. Objectives: To identify and evaluate more thoroughly the roles of Pgp and other substances in mediating drug resistance. Eligibility: Patients enrolled in clinical trials of cancer therapies at the Children's Hospital of Pittsburgh; Cancer Centers of Carolinas; Arizona Clinical Research Center; University of Copenhagen; and Herlev Hospital, Copenhagen who have consented to the use of blood, tissue, or tumor samples for laboratory studies. Design: Blood, tumor, and tissue samples are collected from participants and sent to the NCI for various laboratory analyses. ...

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention.
Kaufhold S, Bonavida B. · · 2014 · cited 342× · PMID 25084828 · DOI 10.1186/s13046-014-0062-0

Verify or expand the search:

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00880503 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 16 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00880503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing